Clinical trial NCT00983151: Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Premature Ejaculation
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2009-09-23
Enrollment: 1050
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug"). The subject and his partner are being asked to be in this clinical trial because they have a condition called premature ejaculation.


Eligibility criteria: Inclusion Criteria:

Subjects are eligible for study participation if all of the following criteria are met:

1. Male subject and female partner to provide written informed consent prior to the performance of any study-specific procedures;
2. Candidates will be male subjects aged 18-65 years inclusive, with lifelong premature ejaculation ("lifelong" is defined as starting at the time the subject became sexually active) with an IELT of ≤120 seconds as documented at Visit 2.
3. History of premature or rapid ejaculation, determined by following criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV TR):

   1. Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after vaginal insertion and before the person wishes it, taking into account factors that affect duration of the excitement phase such as age, novelty of the sexual partner or situation and recent frequency of sexual activity
   2. The disturbance causes marked distress or interpersonal difficulty
   3. The premature ejaculation is not due exclusively to the direct effects of a substance (ab)use
4. In a stable, monogamous, heterosexual relationship (\> 6 months).
5. Willing and able to take study medication as directed at least 2 hours prior to sexual intercourse according to protocol;
6. Subject willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews:
7. Female sexual partner willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews;
8. Able to understand the study procedures, complete the assessments, and communicate with study personnel;
9. Subject and partner willing and able to engage in vaginal intercourse at least three times between visits to yield at least three events of vaginal intercourse ;
10. Subject and partner willing to use a reliable contraceptive method during the trial period if the partner is not menopausal;
11. Partner willing to take pregnancy tests at Visits 1 and 2
12. Subject willing to list and document prescription and non-prescription drug use during the study;
13. Have a negative urine drug screen at Visits 1 and 2;
14. Be in good general health as determined by medical history and physical examination and expected by the Investigator to complete the study as designed.

Exclusion Criteria:

Subjects are not eligible for study participation if any of the following criteria are met:

1. Premature ejaculation attributable to situational or relationship issues;
2. Evidence or a history of other significant psychiatric disorder as defined as requiring therapy or medication;
3. Subjects who in the Investigator's opinion are at significant risk of suicide.
4. Physical illnesses i.History of seizures ii.Prostatitis (current) iii.Urethritis or other urinary tract infections (current) iv.Prior genital surgery (other than vasectomy or circumcision) v.Uncontrolled Diabetes mellitus vi.Respiratory Depression vii.Thyroid disease viii.Chronic moderate to severe neurological disease ix.Significant heart disease treated with cardiac drugs x.Chronic liver disease xi.Chronic kidney disease xii.History of cardiovascular disease (myocardial infarction, congestive heart failure, angina, coronary artery disease or stroke) xiii.Known to be a carrier of the hepatitis B surface antigen, hepatitis C virus antibody, and/or immunodeficiency virus-1 and/ or 2 antibodies xiv.Other disorder that may cause sexual dysfunction
5. Other sexual dysfunction:

   i.Erectile dysfunction. As defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR), the diagnostic criteria for male erectile disorder (302,72) erectile dysfunction includes:

   A.Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate erection.

   B.The disturbance causes marked distress or interpersonal difficulty. ii.Primary reduced sexual desire unrelated to premature ejaculation
6. Sexual intercourse usually less than once per week;
7. Partner sexual dysfunction (for example dyspareunia or other conditions considered relevant);
8. Current use of dapoxetine;
9. Current use of any tramadol;
10. Sensitivity to phenylketone;
11. Any history of abuse of prescription opioids and/or illicit/illegal addictive drugs;
12. Has a known hypersensitivity to heparin or history of heparin induced thrombocytopenia;
13. Use of medication, within the preceding 30 days, with potential to cause sexual dysfunction: (See Appendix 2 for a list of excluded medications) i.Antidepressants - all types

    ii.Antipsychotic medication

    iii.Antihypertensive medication, unless on a stable dose \> 6 months

    iv.Hormonal drugs

    v.Chemotherapy

    vi.Others: cimetidine, clofibrate,quinidine
14. Recent psychotropic drug use (within the past 30 days);
15. A history of alcohol abuse or dependence within the past 6 months as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR);
16. Initiation of psychosexual counseling during the screening, baseline or treatment periods;
17. Partner positive pregnancy test at Visit 1 or 2;
18. History of clinically significant intolerance or a known hypersensitivity to tramadol, such that treatment with it is contraindicated;
19. The Investigator anticipates that the subject will be unable to comply with the protocol;
20. Received any investigational drug within 30 days prior to Visit 1 or is scheduled to receive an investigational drug during the course of this study;
21. Has preplanned surgery or procedures that would interfere with the course of the study.
22. A family member (other than the female partner), a staff member, or relative of a staff member..
23. Significant laboratory abnormality as determined by the Investigator at Visit 1;
24. Significant ECG abnormality at Visit 1 as determined by the Investigator;
25. Any other illnesses, conditions or practices that in the Investigator's opinion could interfere with the collection and/or interpretation of study results (couples using the "Withdrawal Method" of birth control will be excluded from the study).

Primary outcomes:
measure: Increase in IELT (Intravaginal ejaculatory time)
timeFrame: Per attempt at sexual intercourse
Secondary outcomes:
measure: Efficacy of using Tramadol for Premature Ejaculation.
timeFrame: At each attempt
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: Innsbruck Medical university
city: Antwerpen
country: Belgium
facility: Ziekenhuisnelwerk Antwerpen (ZNA), Campus Stuvenberg-St. Erasmus
city: Brussel
country: Belgium
facility: UZ Brussel, Laarbeeklaan 101
city: Bruxelles
country: Belgium
facility: Clinique St. Jean, Depart. of Urology, Blvd du Jardin Botanique, 32
city: Edegem
country: Belgium
facility: Universitair Ziekenhuls Antwerpen (UZA), Wirjkstraat 10
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
city: Liege
country: Belgium
facility: CHU Sart Tilman
city: Cedex
country: France
facility: CHU de Nimes-Groupe Hospitalo-Universitaire, Pharmacie Secteur Essals Cliniques,
city: Garches
country: France
facility: Hopital Raymond Poincar'e, 104 Bvld. Raymond Poincar'e
city: Laval
country: France
facility: Hopital Henry Gabrielle
city: Le Parc Saint Maur
country: France
facility: Porle Bouqueyre
city: Lille
country: France
facility: CETPARPjj
city: Lyon
country: France
facility: hopital Edouard Herriot
city: Marseille
country: France
facility: Institut de Medecine Sexuelle
city: Nice
country: France
facility: Hopital Pasteur
city: Paris
country: France
facility: 11 rue Magellan
city: Paris
country: France
facility: Cabinet medical
city: Rennes
country: France
facility: 76 rue d'Antain, 35700 Rennes
city: Toulouse
country: France
facility: Cabinet medical, 10 rue de la Trinite
city: Frankfurt
country: Germany
facility: Dederweg 2-4
city: Halle
country: Germany
facility: University Hospital Halle
city: Hamburg
country: Germany
facility: Institut fur Mannergesundheit Universitakslinikum Hamburg-Eppendorf
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover Zentrum for Seelische Gesundhelt
city: Koin
country: Germany
facility: Abetellung for Andrologie & Urologie PAN-Kilnik am Neumarkt
city: Muhlheim
country: Germany
facility: PUR/R Praxisklinik Urologie 3 Rhein Ruhr
city: Amsterdam
country: Netherlands
facility: Academic Medical Center, Depart. of Urology
city: Nijmegen
country: Netherlands
facility: Geert Grooteplein Zuid
city: Cordoba
country: Spain
facility: Hospital Universitario Reina Sofla
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Alcordon
city: Malaga
country: Spain
facility: Clinica El Angel
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen de Rocio
city: Eskilstuna
country: Sweden
facility: DW Medical
city: Goteborg
country: Sweden
facility: Carlanderska Sjukhuset
city: Jonkoping
country: Sweden
facility: Urohalsan
city: Lund
country: Sweden
facility: ProbarE AB
city: Solna
country: Sweden
facility: ProbarE AB
city: Stockholm
country: Sweden
facility: Karolinska University hospital-Huddinge
city: Vällingby
country: Sweden
facility: S3 Clinical Research Centers
Study officials:
affiliation: Clinique St Jean
name: Hubert Claes, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bar-Or D, Salottolo KM, Orlando A, Winkler JV; Tramadol ODT Study Group. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol. 2012 Apr;61(4):736-43. doi: 10.1016/j.eururo.2011.08.039. Epub 2011 Aug 30.